Report Highlights

Industry Snapshot

The Prostate Cancer Treatment market was valued at approximately USD 12.8 billion in 2024 and is projected to reach approximately USD 28.6 billion by 2034, growing at a CAGR of 8.4%–9.8% over the forecast period. Prostate cancer is the second most commonly diagnosed cancer in men globally, with approximately 1.4 million new cases and 375,000 deaths annually. The treatment market is in an accelerated growth phase driven by three simultaneous shifts: precision medicine-driven treatment selection through biomarker testing, approval and commercial scale-up of radiopharmaceutical therapy, and increasing use of PARP inhibitor combinations in biomarker-selected patients. The value chain spans five identifiable stages: biomarker testing and diagnostic imaging, small molecule and biologic drug manufacturing, radiopharmaceutical production and distribution, oncology specialty distribution, and clinical administration and monitoring.

The supply chain maturity is heterogeneous by product category. Next-generation hormonal agents are supplied through well-established global pharmaceutical manufacturing and distribution networks with multiple manufacturing sites and developing generic competition. Radiopharmaceuticals represent the most supply chain-immature segment — Novartis' Pluvicto (177Lu-PSMA-617), approved by the FDA in March 2022, launched into immediate supply constraints that persisted for 18 months because commercial-scale lutetium-177 production capacity was not available at launch, forcing allocation systems and patient access limitations that shaped commercial dynamics through 2024.

How This Market Actually Works: Raw Material to End User

The raw material and input layer bifurcates sharply between conventional pharmaceutical inputs (APIs for hormonal agents and PARP inhibitors, standard pharmaceutical excipients, sterile manufacturing consumables) and nuclear medicine inputs for the radiopharmaceutical segment. Lutetium-177 for radioligand therapy is produced by neutron activation of enriched lutetium-176 targets in nuclear reactors — a supply chain beginning at two primary production reactors: the High Flux Reactor in Petten, Netherlands (operated by NRG) and the BR2 reactor in Mol, Belgium (operated by SCK CEN), with secondary production at ILL Grenoble (France) and NRU Chalk River (Canada). Enriched lutetium-176 feedstock itself requires isotope enrichment capability available at fewer than five facilities globally. Small molecule APIs for enzalutamide and abiraterone require specialty chemical synthesis with genotoxic impurity control, typically manufactured at Asian CMOs with finished dose manufacturing at European and North American sterile fill-finish facilities.

The processing and manufacturing layer for radiopharmaceuticals is the most technically complex and capacity-constrained segment in oncology. Lutetium-177 labelling with the PSMA-617 targeting ligand requires hot cell infrastructure — shielded radiopharmaceutical production suites costing USD 5–15 million per production line — that require 2–3 years for regulatory qualification. The 6.7-day half-life of lutetium-177 means finished Pluvicto product must reach clinical sites within 5 days of production, limiting the effective commercial radius of each production facility and requiring air freight at substantially higher cost for distant sites. Lantheus Holdings and Eckert and Ziegler have both invested in new lutetium-177 production capacity since 2022, and Novartis has signed supply agreements with multiple production sites to reduce single-source dependency that constrained its 2022–2023 launch.

The distribution and end-user layer for prostate cancer treatment is governed by the oncology specialty distribution model — predominantly through specialty distributors to academic cancer centres, community oncology practices, and hospital infusion centres. For radiopharmaceutical therapy specifically, the distribution window is severely constrained: Pluvicto must be administered within 24–48 hours of receipt from the production facility, requiring synchronisation of production scheduling, logistics, and patient appointment scheduling that has no parallel in conventional oncology drug distribution. Clinical sites administering radioligand therapy must be licensed nuclear medicine facilities with RSO oversight, restricting the administering site universe to approximately 800–1,000 sites in the US and limiting geographic patient access.

The Demand Signals Reshaping This Supply Chain

The most consequential demand signal is Phase 3 PSMA PET imaging data demonstrating that PSMA-targeted therapy is most effective in patients with PSMA-positive disease confirmed by imaging. This biomarker-driven treatment selection has created an entirely new supply chain link — PSMA PET imaging — that must precede Pluvicto prescription and has itself driven significant nuclear medicine infrastructure investment at academic and community cancer centres. Lantheus Holdings reported over USD 700 million in Pylarify (18F-piflufolastat) revenue in 2024, indicating the imaging diagnostics supply chain is scaling effectively ahead of the radioligand therapy treatment supply.

PARP inhibitor combination demand is reshaping the DNA damage repair biomarker testing supply chain. The approvals of olaparib plus abiraterone and niraparib plus abiraterone for mCRPC patients with homologous recombination repair gene mutations have created immediate demand for HRR biomarker testing at diagnosis and disease progression. Foundation Medicine and Tempus are the primary CDx partners delivering validated HRR testing for treatment selection, and their testing volume is directly correlated with PARP inhibitor market penetration. A bottleneck at the diagnostic testing step creates a downstream demand constraint for the PARP inhibitor — making testing access a supply chain management priority for PARP inhibitor manufacturers.

Where This Supply Chain Is Fragile

The lutetium-177 production concentration risk is the most acute structural supply chain fragility in the prostate cancer treatment segment. Two nuclear reactors — HFR Petten and BR2 Mol — produce approximately 60%–65% of commercial medical lutetium-177. Both are ageing infrastructure: HFR Petten was commissioned in 1961, BR2 Mol in 1963. Unplanned outages at either facility — as occurred at HFR Petten in 2023 for a 6-week maintenance shutdown — directly interrupt Pluvicto supply and require patient appointment rescheduling at treating centres globally. The commercial-scale lutetium-177 capacity under development at new production sites (Niowave in Michigan, NorthStar Medical Radioisotopes in Wisconsin) will provide geographic redundancy by 2026–2027, but until these sites achieve full regulatory qualification, the market remains structurally dependent on two 60-year-old European research reactors for the majority of its fastest-growing product category.

The demand-side constraint most significantly limiting market penetration of optimal therapies is biomarker testing access in community oncology. Approximately 55%–60% of prostate cancer patients in the US are treated at community oncology practices without integrated molecular pathology capabilities, and HRR biomarker testing uptake prior to mCRPC second-line treatment remains below 40% in community settings despite clinical guideline recommendations. This testing access gap is a direct demand constraint for PARP inhibitors and creates both an equity issue and a commercial opportunity for testing access improvement programs.

Market at a Glance

The Geography of Production, Processing, and Demand

North America functions as the primary demand centre for prostate cancer treatment, representing approximately 48% of global revenue, driven by high diagnosis rates, broad specialist access, and premium pricing in the US market. North America is also an emerging production centre for radiopharmaceuticals, with DoE Isotope Program and private investment driving new lutetium-177 production capacity at NorthStar, Niowave, and a planned Lantheus production facility. The most significant supply chain event expected in North America through 2030 is the commissioning of domestic US lutetium-177 production at sufficient scale to reduce European production dependency — reducing supply chain transit time from 2–3 days to same-day or next-day, materially improving product quality at administration. Europe functions as the primary production centre for radioligand therapy and as a significant demand market. Asia Pacific is the fastest-growing demand region, driven by increasing diagnosis rates in China, Japan, and South Korea as PSA screening adoption improves.

China represents the most complex country-level supply chain situation: demand is growing rapidly at approximately 8% annually as screening improves, but the supply chain for novel agents is constrained by regulatory approval timelines running 18–36 months behind US approvals and by the absence of commercial-scale PSMA PET imaging infrastructure outside top-tier cancer centres. Domestic Chinese pharmaceutical companies — Hengrui Medicine, Zymeworks China — have both in-licensed and internally developed next-generation hormonal agent biosimilars that will capture share in the Chinese market from international brands as they achieve NMPA approval from 2025 onward.

Who Controls Each Layer of This Value Chain

Within-tier competition is most intense at the next-generation hormonal agent level, where four approved drugs — enzalutamide (Astellas/Pfizer), abiraterone (Janssen/generic), darolutamide (Bayer), and apalutamide (Janssen) — compete across overlapping indications. Competitive dynamics have shifted from clinical differentiation to total cost of therapy arguments as generic abiraterone reduced the reference price point. At the PARP inhibitor level, olaparib (AstraZeneca/Merck) and niraparib (Janssen) compete in HRR-selected populations with companion diagnostic co-development strategies creating switching costs through validated biomarker-drug pairing. At the radiopharmaceutical level, Novartis holds a near-monopoly with Pluvicto in the approved PSMA-targeted RLT space.

Cross-tier vertical integration is actively underway in the radiopharmaceutical segment. Novartis acquired Advanced Accelerator Applications in 2018 for radioligand therapy manufacturing capability, then Endocyte in 2018 for the PSMA-617 ligand — a 5-year vertical integration trajectory creating the most integrated radioligand therapy supply chain globally. Eli Lilly's USD 1.4 billion acquisition of POINT Biopharma in 2023 and AstraZeneca's Fusion Pharmaceuticals acquisition in 2024 for USD 2 billion represent the pharmaceutical industry's recognition that radioligand therapy vertical integration is the competitive necessity of the next decade. Companies that do not control their radioisotope sourcing and production infrastructure will face supply chain vulnerability and margin compression as the RLT market scales.

Leading Market Participants

• AstraZeneca (olaparib in partnership with Merck)
• Johnson and Johnson (enzalutamide, apalutamide, niraparib)
• Novartis (Pluvicto, Xofigo)
• Pfizer (enzalutamide co-promotion)
• Bayer (darolutamide, radium-223)
• Astellas Pharma (enzalutamide)
• Bristol-Myers Squibb (nivolumab combinations in development)
• Lantheus Holdings (PSMA PET imaging, RLT production)
• Merck (olaparib in partnership with AstraZeneca)
• Sanofi (cabazitaxel)

Long-Term Market Perspective

By 2034, the prostate cancer treatment supply chain will be measurably more integrated at the radiopharmaceutical tier and more competitive at the conventional small molecule tier. Lutetium-177 production capacity will have expanded to include at least five commercial-scale sites in the US and Europe, reducing single-facility dependency risk. Next-generation radioligand therapies — actinium-225 conjugates, alpha-emitting radioligand therapies — will be entering Phase 3 trials, and the commercial-scale supply chain for actinium-225 (currently available only in microgram quantities globally) will be the next critical radioisotope supply constraint to develop.

Capital investment priorities through 2034 are radiopharmaceutical production infrastructure (the value chain stage with the highest barrier, highest margin, and most acute capacity constraint), biomarker testing access programs (the demand enabler for precision medicine approaches), and clinical development for next-generation alpha-emitting radioligand therapies. The one development most underweighted in mainstream analysis is the potential for prostate cancer ctDNA-based liquid biopsy to become the standard HRR testing method by 2028, replacing tissue biopsy as the treatment selection tool — a shift that would dramatically increase testing rates and PARP inhibitor eligible patient identification by removing the tissue acquisition barrier from the diagnostic pathway.